Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of JS203 plus chemotherapy versus rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma
CTR20263421Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of JS203, rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
JS203rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20263421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263421.